Top 5 bladder cancer articles of 2017
A look at Urology Times' most-read articles on bladder cancer reveals a variety of topics, ranging from radical cystectomy to the role of protein- and cell-based urinary biomarkers for bladder cancer detection and surveillance.
A look at Urology Times' most-read articles on bladder cancer reveals a variety of topics, ranging from radical cystectomy to the role of protein- and cell-based urinary biomarkers for bladder cancer detection and surveillance. As part of our review of 2017, these are our top 5 most-read articles on bladder cancer:
Radical cystectomy for bladder cancer: Tools vs. technique
Robert Abouassaly, MD, MS, discusses important principles of radical cystectomy, whether performed using the open, laparoscopic, or robotic approach. Read more
Novel bladder Ca agent shows promise in phase II trial
An investigatory bladder cancer agent was associated with a 12-month high-grade recurrence-free survival of 35% for patients with Ta/T1 disease, researchers reported. Read more
Robotic vs. open cystectomy: How PFS, OS compare
Evaluation of upper tract surveillance for high-grade NMIBC and evidence that androgen receptor activity may be related to recurrence of bladder cancer were among other take-home messages from AUA 2017. Read more
Bladder cancer test shows high sensitivity
The noninvasive molecular test for detecting recurrent urothelial carcinoma also demonstrates high negative predictive value in a prospective study. Read more
Biomarkers for bladder cancer: Current and future
The role of protein- and cell-based urinary biomarkers for bladder cancer detection and surveillance is controversial, and in 2017 these assays have yet to come into widespread use among urologists. Their uptake is expected to increase, however, considering that the American Urological Association/Society of Urologic Oncology “Guideline on Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer” that was released in 2016 identifies situations for using urinary biomarkers, according to Badrinath R. Konety, MD. Read more
More from Urology Times:
Top 5 Dr. Rosevear blogs of 2017
Top 9 peer-reviewed prostate cancer papers of 2017
Top 12 practice management articles of 2017
To get weekly news from the leading news source for urologists, subscribe to the Urology Times eNews.
Cell therapy TARA-002 shows initial promise in NMIBC
April 9th 2024"This encouraging anti-tumor activity coupled with a favorable safety profile and mode of administration that is both convenient and familiar to urologists indicates that, if confirmed in future studies, TARA-002 could potentially play a meaningful role in NMIBC treatment in the future," says Timothy D. Lyon, MD.
Nadofaragene firadenovec shows durable efficacy in NMIBC
April 8th 2024"In this follow-up analysis of the phase 3 study, we demonstrated a sustained response to Adstiladrin treatment over 3 years, allowing more than half of the patients in the study to remain cystectomy free for at least 36 months,” says Colin P.N. Dinney, MD.
